← Human Trials & Peer-Reviewed Studies
Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development
Plain-language guide to PMID 16377065 (2006): randomized controlled trial of hCG (human chorionic gonadotropin) and Triptorelin.
Key Facts
- PMID
- 16377065
- Journal
- European journal of obstetrics, gynecology, and reproductive biology
- Year
- 2006
- Study type
- Randomized Controlled Trial
- Authors
- Krause BT et al. (2 authors)
- DOI
- 10.1016/j.ejogrb.2005.11.013
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of hCG (human chorionic gonadotropin) and Triptorelin, published as a randomized controlled trial.
But conflicting results are reported on the efficiency of subsequent luteal support using hCG and/or progesterone supplementation.
Who Took Part
By PubMed's age tags, the people studied were adults, women only.
The monitoring of the ovulation period and the subsequent luteal phase included sonographic measurement of ovarian diameter and estimation of LH, FSH, estradiol and progesterone levels 10 and 34 h as well as 8 days after Triptorelin administration.
How the Study Was Run
The design is described as randomized.
Random assignment meant chance, not the researchers, decided who got hCG (human chorionic gonadotropin) and who got the comparison, which limits bias.
A risk for an imminent ovarian hyperstimulation was assumed if preovulatory estradiol levels rose up higher than 700 pg/ml and more than 12 intermediate sized follicles (8-14 mm) were observed.
After randomization, luteal support regimes started on day 2 after the Triptorelin administration with injections every second day five times in all.
What Was Measured
PubMed files the paper under topics including Chorionic Gonadotropin, Estradiol, Follicle Stimulating Hormone, Follicular Phase, Gonadotropin-Releasing Hormone, Luteal Phase and Luteinizing Hormone.
What This Means in Plain Language
The paper is a randomized study of hCG (human chorionic gonadotropin) and Triptorelin.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2006 (European journal of obstetrics, gynecology, and reproductive biology), a journal based in Ireland.
More context: the hCG (human chorionic gonadotropin) compound page and the Triptorelin compound page, all human trials.
Our Notes on the Compounds
hCG (human chorionic gonadotropin): An LH analog that drives Leydig-cell testosterone production.
Triptorelin: A 10-amino-acid GnRH analog (Trelstar, Decapeptyl, Triptodur) used in prostate cancer, early puberty and fertility protocols.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.